Key facts
- This page summarizes Robert J. Priar's Form 4 filing for Bionano Genomics, Inc (BNGO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Jun 2021, 17:03.
Robert J. Priar - 01 Jun 2021 Form 4 Insider Report for Bionano Genomics, Inc (BNGO)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- BNGO
- Reported as of
- 01 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ R. Erik Holmlin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Robert J. Priar filed Form 4 for Bionano Genomics, Inc (BNGO) on 08 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNGO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +400,000
- Change %
- Price
- $0.000000
- Shares after
- 400,000
- Date
- 01 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400,000
- Exercise price
- $6.32
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of the shares subject to the option shall vest and become exercisable on June 1, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from June 1, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2018 Equity Incentive Plan) through each such applicable vesting date and the terms of the Company's 2018 Equity Incentive Plan.